CHAPTERS
- 0:00 – 2:11
Peptides targeted by regulators: what’s actually happening and why it matters
Joe and Brigham frame the current “war on peptides” as a regulatory move that effectively destroys access without an outright ban. They set up the central claim: the action is less about safety and more about protecting profit and market control.
- •FDA actions are described as reclassification rather than a formal ban
- •Argument that there’s no clear public-health crisis driving restrictions
- •Claim that patented peptides remain untouched while others are targeted
- •Theme introduced: incentives and capture drive policy outcomes
- 2:11 – 4:31
A history lesson on pharma misconduct and the “medical‑industrial complex”
Brigham argues that to understand peptide policy, you have to understand the historical pattern of private industry influencing government. He cites notorious examples and ties them to Eisenhower’s warning about the medical-industrial complex.
- •Allegations of unethical clinical testing during WWII-era industry growth
- •Eisenhower’s warning extends beyond military to medicine and healthcare
- •Recurring theme: profit prioritized over patient outcomes
- •Establishes the lens of regulatory capture and institutional incentives
- 4:31 – 7:14
From HIV contamination to opioids: recurring incentives and repeat failures
The conversation moves through examples meant to show how companies and regulators behave when profit conflicts with safety. Brigham connects these stories to why he believes peptide access is being squeezed now.
- •Hemophilia drug contamination and overseas dumping example is cited
- •Litigation against low-cost HIV treatment efforts is described
- •Opioid crisis referenced as an example of sanctioned harm
- •Conclusion: the same incentive structure explains peptide restrictions
- 7:14 – 8:44
How peptides get ‘killed’ without a ban: dangerous lists, patents, and market signals
Brigham explains the mechanism: labeling compounds as “dangerous” chills physician prescribing and collapses legitimate supply. He contrasts targeted peptides with patented peptide drugs that remain widely available.
- •Over 7,000 peptides exist; only certain ones are targeted
- •GLP-1s and insulin are described as protected/patented peptides
- •Patents focus on delivery and dosing rather than the molecule itself
- •Reclassification discourages doctors due to litigation and licensing risk
- 8:44 – 17:33
PBMs, insurers, and DOJ pressure: how enforcement shapes medical behavior
Brigham claims insurers and PBMs can effectively weaponize enforcement by feeding narratives and data to prosecutors. He uses the out-of-network billing dynamic to illustrate how normal business realities can be reframed as fraud.
- •Out-of-network reimbursement forces inflated billed charges to net fair payment
- •Insurers then cite high billed charges as evidence of wrongdoing
- •Indictment dynamics: reputational damage, limited defense window
- •Asset seizure described as a compounding threat once indicted
- 17:33 – 20:56
Compounding pharmacy safety vs Big Pharma manufacturing: who gets scrutinized?
Brigham outlines sterility, sourcing, third-party testing, and documentation practices he says reputable compounders follow. He contrasts that with claims of infrequent inspection and offshore manufacturing vulnerabilities in large pharma supply chains.
- •Ingredient verification, ISO environments, and batch testing described
- •Chain-of-custody documentation emphasized end-to-end
- •Claim: many pharma facilities go years without inspection
- •Offshoring plus advance notice allegedly undermines inspection integrity
- 20:56 – 25:00
GLP‑1s, shortages, and lawsuits: compounding as a workaround—and a target
They discuss GLP‑1 shortages and how compounding pharmacies produce alternative doses during backorders. Brigham argues pharma then sues compounders while running PR campaigns that portray compounding as unsafe.
- •GLP-1s framed as diabetes drugs repurposed for weight loss demand
- •Backorder status enables compounding under existing rules
- •Pharma lawsuits and PR narratives described as competitive strategy
- •Shortages attributed in part to manufacturing and compliance issues
- 25:00 – 39:10
Media incentives and the revolving door: pandemic fallout and trust collapse
Joe and Brigham connect pharma influence to advertising-driven media coverage and public distrust after COVID-era messaging. They also discuss regulators moving into industry roles as evidence of revolving-door incentives.
- •Media dependence on pharma ad dollars discussed as a bias vector
- •Pandemic coverage cited as a credibility-breaking moment
- •Revolving door example: FDA leaders joining Moderna is cited
- •Broader claim: institutions become aligned with industry interests
- 39:10 – 47:44
Devices, 510(k), and underreported adverse events: why ‘approved’ doesn’t mean safe
Brigham pivots to medical devices, arguing the 510(k) pathway allows widespread use without human safety trials. He shares rep-era anecdotes about sterile processing, contamination risk, and underreporting of adverse events.
- •510(k) described as a daisy-chain equivalence pathway
- •Claim: most OR products enter via 510(k), not full clinical validation
- •Anecdotes: tissue residue in instruments and sterilization limitations
- •Example of cross-use between veterinary and human surgery equipment
- 47:44 – 48:56
Why he built Ways2Well & Revive: escaping insurance and building cash‑pay care
Brigham explains his entrepreneurial arc: opioid loss in his family, building alternatives, and being crushed by insurance reimbursement changes. He argues cash-pay models enable root-cause care, testing, and flexibility that insurance discourages.
- •Motivation: non-addictive pain and healing alternatives after opioid loss
- •Insurance refusals and sudden reimbursement cuts as existential risks
- •Cash-pay positioned as the only workable model for prevention and longevity
- •Joe shares personal benefit from peptides/stem cells for injury recovery
- 48:56 – 1:04:03
Testosterone, medical dogma, and the PBM-driven formulary machine
They use testosterone therapy as an example of how long debunked ideas can persist in mainstream medicine. Brigham then expands into PBMs, rebates, and tiering systems that he claims prioritize profitability over outcomes.
- •Morgentaler and the “saturation model” used to challenge prostate-cancer fears
- •Example of how weak early studies can calcify into decades of dogma
- •PBMs explained as intermediaries controlling coverage and drug tiers
- •Insulin pricing cited as a case study in rebates and spread profits
- 1:04:03 – 1:42:12
The future: AI/LLMs for personalized medicine—and the privacy/insurance risk
Brigham lays out a vision where large language models help scale proactive, data-driven care by integrating EMRs, imaging, labs, and wearables. They also discuss bias, closed vs open data systems, and the danger of insurers using AI to deny care.
- •LLMs described as tools for continuous monitoring and decision support
- •Closed infrastructure proposed to control data quality and reduce bias
- •Automation: charting, recall of history, and triage to reduce clinician burden
- •Major warning: insurers could use AI + wearables to restrict or price care
- 1:42:12 – 1:50:55
Brain mapping, magnets (MeRT), and psychedelics research for performance and mental health
They explore EEG-based diagnostics and magnet-based neuro-optimization approaches, including potential applications in high-performance settings. Brigham also mentions collaborations around psychedelic microdosing research to quantify cognitive effects.
- •EEG + AI reporting to identify signal loss across brain regions
- •MeRT described as frequency-tuned magnetic stimulation
- •Use cases: concussion-related depression, high-pressure operators, performance
- •Talks with Dell Medical and Bruce Damer on low-dose psychedelic research
- 1:50:55 – 2:04:00
Stem cells explained: signaling vs differentiation, regulation limits, and athlete recoveries
Returning from a break, they go deep on what’s legally allowed in the U.S. and what people misunderstand about mesenchymal signaling cells. Brigham emphasizes mechanism-of-action, clinical expectations, and highlights athlete recovery stories including Aaron Rodgers.
- •U.S. limits: ‘minimally manipulated’ tissue; expansion constraints discussed
- •MSCs framed as signaling/repair orchestration rather than direct differentiation
- •Dose debate: ‘more is better’ vs minimal effective dose with low risk
- •Examples from pro sports and Aaron Rodgers’ multidisciplinary recovery
- 2:04:00 – 2:14:34
OA knees, cartilage questions, and closing message: optimize healing and build hope
They discuss osteoarthritis evidence, what current studies suggest about cartilage loss, and where regenerative approaches may head next. The episode closes with a broad critique of profit-driven medicine, a call for proactive care, and Brigham’s hiring pitch.
- •Study discussed on umbilical cord-derived MSCs for knee OA outcomes
- •Clarifies ‘slowing loss’ vs true cartilage regeneration as the key question
- •Reinforces: combine surgery with optimization (red light, hyperbaric, peptides)
- •Ends with optimism, future tech (CRISPR teased), and recruiting talent
